INTRODUCTION
Ulcerative colitis (UC) is a chronic mucosal inflammatory condition that can affect any part of the colon, and is characterized by periods of remission and active disease associated with symptoms of abdominal pain, diarrhea, rectal bleeding, and fecal urgency [1, 2] . While the complete etiology of UC remains unclear, risk factors include genetic predisposition, history of bacterial infections, and lifestyle factors [1] .
Approximately 50% of patients with quiescent UC may relapse within a given year [3] , highlighting the importance of treatments that enable effective management of the disease.
Mesalamine (5-aminosalicylic acid ), a locally acting, anti-inflammatory compound that reduces inflammation of the colonic mucosa, is recommended first-line treatment for patients with mild-to-moderate UC [4] [5] [6] .
Available in both oral and topical formulations, 5-ASA is generally well tolerated and has proven to be effective in symptom improvement as well as in the induction and maintenance of UC remission [5, [7] [8] [9] [10] . For 5-ASA to be effective in treating mild-to-moderate UC, the drug must be able to directly target the mucosa of the terminal ileum and colon, where it negatively regulates cyclooxygenase and lipoxygenase pathways to prevent formation of prostaglandin and leukotrienes [11] , and increases the expression of peroxisome proliferator-activated receptors [12] . Immediate-release oral mesalamine formulations result in the quick absorption of 5-ASA in the upper gastrointestinal (GI) tract, with systemically absorbed drug having little clinical effect [13, 14] . Therefore, some Horsham, PA, USA) [22] . The USP apparatus type was selected as such to permit placement of the respective drug forms (capsule or tablet) into the dissolution media for the duration of the test without interfering with the ability to observe them.
To investigate the effect of simulated GI conditions on release of active 5-ASA, dissolution testing was performed in 3 stages. An initial acid stage (2 h at pH 1.0) was followed by a 2-part buffer stage (1 h at pH 6.0 followed by 8 h at pH 6.8; Table 1 ). The dissolution bath was maintained at a mean (±standard deviation
[SD]) temperature of 37°C (±5°C), and the quantitative determination of the amount of 
RESULTS
The dissolution profiles of all tested mesalamine formulations are shown in Fig. 1 . The APRISO formulation demonstrated consistent release of 5-ASA across individual capsules at each pH (see Table 2 for SDs at pH 6.8). After 2 h at pH 1.0, 1% of 5-ASA was released; a total of 36% of 5-ASA 
DISCUSSION
As the pH profile in the colon can vary in patients with UC, with pH\7.0 reported in some cases, non-homogenous release of 5-ASA for enteric-coated, pH-dependent formulations may occur [19, [23] [24] [25] . In the current study, the dissolution rates of different mesalamine formulations were compared at pH 6.8. Results revealed a high degree of variation in release profiles across different formulations.
All tested mesalamine formulations, except for the PENTASA formulation, had little to no release of 5-ASA at pH 1.0, while varying degrees of 5-ASA release were observed at pH 6.0 and pH 6.8. The PENTASA formulation released 5-ASA in a manner independent of pH level, with steady continuous release over time. In general, the enteric coatings of the other tested formulations were designed to dissolve at higher pH levels, such as those typically observed in the lower sections of the GI tract.
After 1 h at pH 6.0, the APRISO formulation released more than one-third of its active 5-ASA. Both the ASACOL MR and ASACOL HD formulations did not release the active drug at pH 6.0; 3 of 6 tested ASACOL MR tablets did not release any drug for the first hour at pH 6.8, while drug release across ASACOL HD tablets at pH 6.8 was more consistent. In a prior study by Spencer et al. [21] , release of 5-ASA from the ASACOL 400-mg tablets at pH\7.0 exhibited considerable variability from tablet to tablet, though more consistent release was observed at pH 7.2. In that study, USP apparatus II was used to test dissolution of the ASACOL tablet in a similarly staged acid and buffer procedure: 2 h at pH 1.2 stirring at 50 rpm, 1 h at pH 6.0 stirring at 100 rpm, and finally 1.5 h at either pH 6.5, 6.8, or 7.2 stirring at 50 rpm. While 100% of 5-ASA was released from the ASACOL tablets within 2 h at pH 7.2, complete release of 5-ASA was observed after 5 h at pH 6.8, whereas only approximately 50% of 5-ASA was released after 6 h at pH 6.5. Although it was postulated that differences in tablet film-coat thickness could account for the variability in 5-ASA release from the tablets, a direct correlation between film-coat thickness and dissolution performance could not be made [21] . It should be noted that the ASACOL 400-mg tablets examined by Spencer et al. [21] are no longer commercially available, and differ from the ASACOL HD 800-mg and the ASACOL MR 800-mg formulations currently investigated.
The current study demonstrated complete release of 5-ASA from the ASACOL tablets within 2 h (ASACOL HD formulation) to 4 h (ASACOL MR formulation) at pH 6.8, with high tablet-to-tablet variability observed in the latter.
Without additional insight into the formulation or manufacturing process for either ASACOL HD or ASACOL MR, it remains unclear why the dissolution profiles of these two formulations differed from one other.
In contrast to the ASACOL MR formulation, 5-ASA release from other formulations (PENTASA, APRISO, MEZAVANT XL, and SALOFALK) was found to be relatively consistent between tablets at pH 6.8. The MEZAVANT XL formulation did not release any drug at pH 6.0, but exhibited complete drug release within 6-7 h at pH 6.8. Another study examining the release profile of 5-ASA from the MEZAVANT XL formulation [26] also revealed minimal tablet-to-tablet variation, and this observation was associated with consistent film-coat thickness among the tablets examined. Finally, the SALOFALK tablets released 11% of 5-ASA at pH 6.0, then exhibited rapid release of the remainder of its 5-ASA in less than 1 h at pH 6.8.
Results from D'Inca and colleagues [27] showed that mesalamine formulations with pH-dependent release achieved significantly higher mucosal concentrations of 5-ASA within the diseased colon in patients with UC compared with time-dependent mesalamine release formulations or pro-drugs. However, it remains unclear whether the current study findings regarding variability of release in vitro have an effect in vivo. Thus, the clinical relevance of these findings remains to be elucidated.
CONCLUSIONS
In summary, significant variations were observed between the dissolution profiles of 6 mesalamine formulations examined at a range of pH values, with a few formulations also exhibiting wide tablet-to-tablet variation in the release of 5-ASA. However, it is still not known whether a correlation exists between the in vitro dissolution profiles of these formulations and their release characteristics in the colon. Additional studies will be needed to determine if these findings are clinically relevant. 
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